You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明康德(02359.HK)药明生物(02269.HK)涨5%及8.5%齐创纪录高
阿思达克 07-13 15:17
药明生物(02269.HK)连升第五天,今天股价再突破6月29日盘中所创纪录高位150.8元,最高见158.9元,现造157.8元,续升8.5%,成交增至747万股,涉资11.53亿元。其母企药明康德(02359.HK)继上周五稍作整固後,今天股价也再创上市新高,最高见113.4元,现造113.2元,回升5%。

药明生物6月30日公布,与配售代理订立以每股137元(较前个交易日折让7.9%)配售4,500万股协议,所得款项拟用於持续全球扩张,包括为治疗新冠肺炎及其他相关CDMO项目而於美国兴建商业生产设施、於中国境外收购生产设施及於中国兴建微生物产品设施等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account